{"SLR NAME":"Coronavirus disease 2019 (COVID-19) in solid organ transplantation: systematic review","References":[{"title1":"COVID-19 in solid organ transplant recipients: A single-center case series from Spain","References":[{"title2":"A novel coronavirus from patients with pneumonia in China, 2019","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition"},{"title3":"Importation and human-to-human transmission of a novel coronavirus in Vietnam"},{"title3":"2019 novel coronavirus (2019-nCoV) outbreak: a new challenge"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan"},{"title3":"Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China"},{"title3":"Novel Wuhan (2019-nCoV) coronavirus"},{"title3":"Severe acute respiratory syndrome coronavirus phylogeny: toward consensus"},{"title3":"Diagnosis and treatment of new coronavirus pneumonia (trial version 7) [J / OL]. Tianjin J Tradit Chin Med. 2020;1-5. http://kns.cnki.net/kcms/detail/12.1349.R.20200304.1638.006.html. Accessed 3 June 2020."},{"title3":"Clinical outcome of standardized oxygen therapy nursing strategy in COVID-19"},{"title3":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study"},{"title3":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission"},{"title3":"Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus"},{"title3":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection"},{"title3":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation"},{"title3":"Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways"},{"title3":"Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome"},{"title3":"Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV"},{"title3":"Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients"},{"title3":"Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study"},{"title3":"C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early"},{"title3":"Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study"},{"title3":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China"},{"title3":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Human ipsc-derived cardiomyocytes are susceptible to Sars-Cov-2 infection"},{"title3":"Cardiovascular complications in COVID-19"},{"title3":"COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?"},{"title3":"Endothelial cell infection and endotheliitis in COVID-19"}]},{"title2":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","References":[{"title3":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses"},{"title3":"Coronavirus avian infectious bronchitis virus"},{"title3":"Pathogenicity of turkey coronavirus in turkeys and chickens"},{"title3":"Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin"},{"title3":"Severe acute respiratory syndrome"},{"title3":"SARS: epidemiology"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"A dynamic compartmental model for the Middle East respiratory syndrome outbreak in the Republic of Korea: a retrospective analysis on control interventions and superspreading events"},{"title3":"The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015"},{"title3":"A novel coronavirus genome identified in a cluster of pneumonia cases:Wuhan, China 2019-2020"},{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Two-tube multiplex real-time reverse transcription PCR to detect six human coronaviruses"},{"title3":"Fast and accurate short read alignment with Burrows-Wheeler transform"},{"title3":"RAPSearch2: a fast and memory-efficient protein similarity search tool for next-generation sequencing data"},{"title3":"Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: virological and clinical findings"},{"title3":"CDD/SPARCLE: functional classification of proteins via subfamily domain architectures"},{"title3":"Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination"},{"title3":"Parallelization of MAFFT for large-scale multiple sequence alignments"},{"title3":"RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies"},{"title3":"Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats"},{"title3":"Structure, function, and evolution of coronavirus spike proteins"},{"title3":"Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond"},{"title3":"MERS-CoV spike protein: targets for vaccines and therapeutics"},{"title3":"Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine"},{"title3":"Evidence for a common evolutionary origin of coronavirus spike protein receptor-binding subunits"},{"title3":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"},{"title3":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26"},{"title3":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4"},{"title3":"Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26"},{"title3":"SWISS-MODEL: homology modelling of protein structures and complexes"},{"title3":"Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody"},{"title3":"Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China"},{"title3":"Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia"},{"title3":"Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin"}]},{"title2":"World Health Organization (WHO). Coronavirus disease 2019 (COVID-19). Situation Report 67. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200327-sitrep-67-covid-19.pdf?sfvrsn=b65f68eb_4. Accessed March 28, 2020.","References":[]},{"title2":"Instituto de Salud Carlos III, Centro Nacional de Epidemiologia. Informe sobre la situacion de COVID-19 en Espana no 16 (26 de marzo de 2020). https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20no%2016.%20Situacion%20de%20COVID-19%20en%20Espana%20a%2026%20marzo%20de%202020.pdf. Accessed March 28, 2020.","References":[]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: adescriptivestudy"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever"},{"title3":"Coronavirus infections-more than just the common cold"},{"title3":"The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study"},{"title3":"Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill"},{"title3":"Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study"}]},{"title2":"Influenza and other respiratory virus infections in solid organ transplant recipients","References":[{"title3":"Respiratory viral infections in transplant recipients"},{"title3":"Influenza, including the novel H1N1, in organ transplant patients"},{"title3":"Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies"},{"title3":"RNA respiratory viruses in solid organ transplantation"},{"title3":"Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection"},{"title3":"Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study"},{"title3":"Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients"},{"title3":"Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine"},{"title3":"Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study"},{"title3":"Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI)"},{"title3":"Pandemic (H1N1) 2009 infection in adult solid organ transplant recipients in Singapore"},{"title3":"The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients"},{"title3":"Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients"},{"title3":"Influenza virus infection in adult solid organ transplant recipients"},{"title3":"Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study"},{"title3":"Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature"},{"title3":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus"},{"title3":"Pandemic influenza A/H1N1 virus infection in solid organ transplant recipients: a multicenter study"},{"title3":"Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome"},{"title3":"Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy"},{"title3":"Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study"},{"title3":"A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients"},{"title3":"Clinical and radiological features of respiratory syncytial virus in solid organ transplant recipients: a single-center experience"},{"title3":"Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function"},{"title3":"Chronic rhinoviral infection in lung transplant recipients"},{"title3":"The human polyomaviruses KI and WU: virological background and clinical implications"},{"title3":"Molecular detection of respiratory viruses"},{"title3":"Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation"},{"title3":"Influenza vaccination in the organ transplant recipient: review and summary recommendations"},{"title3":"Deficient long-term response to pandemic vaccine results in an insufficient antibody response to seasonal influenza vaccination in solid organ transplant recipients"},{"title3":"Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort"},{"title3":"Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease"},{"title3":"Outcomes associated with influenza vaccination in the first year after kidney transplantation"},{"title3":"Serologic vaccination response after solid organ transplantation: a systematic review"},{"title3":"Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients"},{"title3":"Impact of anti-T-cell therapy in the immunogenicity of seasonal influenza vaccine in kidney transplant recipients"},{"title3":"Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine"},{"title3":"Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients"},{"title3":"AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial"},{"title3":"Vaccination in solid organ transplantation"},{"title3":"De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients"},{"title3":"From the American Academy of Pediatrics: Policy statements:modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections"},{"title3":"Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial"},{"title3":"Antivirals and resistance: influenza virus"},{"title3":"Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients:North Carolina, 2009"},{"title3":"Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients"},{"title3":"Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation"},{"title3":"Respiratory syncytial virus lower respiratory tract infection in a pediatric liver transplant recipient treated with oral ribavirin"},{"title3":"Oral ribavirin therapy for lower respiratory tract infection of respiratory syncytial virus complicating bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation"},{"title3":"Changes in severity of influenza A(H1N1)pdm09 infection from pandemic to first postpandemic season, Germany"},{"title3":"Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections"},{"title3":"Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient"},{"title3":"Long-term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiency"},{"title3":"Successful clearance of human parainfluenza virus type 2 viraemia with intravenous ribavirin and immunoglobulin in a patient with acute myocarditis"},{"title3":"The management of coronavirus infections with particular reference to SARS"},{"title3":"Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin"},{"title3":"Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin"},{"title3":"Treatment with oral ribavirin and IVIG of severe human metapneumovirus pneumonia (HMPV) in immune compromised child"},{"title3":"Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics"}]},{"title2":"Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection","References":[{"title3":"Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009"},{"title3":"Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans"},{"title3":"Update: novel influenza A (H1N1) virus infections - worldwide, May 6, 2009"},{"title3":"Emergence of a novel swine-origin influenza A (H1N1) virus in humans"},{"title3":"Influenza-associated hospitalizations in the United States"},{"title3":"Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009"},{"title3":"Guidance on novel influenza A/H1N1 in solid organ transplant recipients"},{"title3":"Influenza virus infection in adult solid organ transplant recipients"},{"title3":"Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study"},{"title3":"Pandemic (H1N1) 2009 Infection in Adult Solid Organ Transplant Recipients in Singapore"},{"title3":"Pandemic influenza A/H1N1 virus infection in solid organ transplant recipients: a multicenter study"},{"title3":"Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung"},{"title3":"Hospitalized patients with novel influenza A (H1N1) virus infection - California, April-May, 2009"},{"title3":"Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009"},{"title3":"Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009"},{"title3":"Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections"},{"title3":"Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009"},{"title3":"A prediction rule to identify low-risk patients with community-acquired pneumonia"},{"title3":"Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study"},{"title3":"Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain"},{"title3":"Influenza A in immunocompromised patients"},{"title3":"Nosocomial outbreak of influenza virus A (H3N2) infection in a solid organ transplant department"},{"title3":"Nosocomial swine influenza (H1N1) pneumonia: lessons learned from an illustrative case"},{"title3":"2009 H1N1 Influenza in Hospitalized Transplant Recipients"},{"title3":"Severe novel H1N1 influenza A infection in the immediate postoperative period of a liver transplant patient"},{"title3":"Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico"},{"title3":"Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome"},{"title3":"Patients hospitalized with 2009 pandemic influenza A (H1N1) - New York City, May 2009"},{"title3":"Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza"},{"title3":"Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK"}]},{"title2":"Comparison of the SpO2/FiO2 ratio and the PaO2/FiO2 ratio in patients with acute lung injury or ARDS","References":[]},{"title2":"Acute respiratory distress syndrome: the Berlin Definition","References":[]},{"title2":"Ministerio de Sanidad. Centro de Coordinacion de Alertas y Emergencias Sanitarias. Documento tecnico de manejo clinico de pacientes con enfermedad por el nuevo coronavirus (COVID-19) (version 3 de Marzo de 2020). https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Protocolo_manejo_clinico_COVID-19.pdf. Accessed March 21, 2020.","References":[]},{"title2":"Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients","References":[]}]},{"title1":"First case of COVID-19 in a kidney transplant recipient treated with belatacept","References":[{"title2":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. [published online ahead of print March 11, 2020] Lancet. https://linkinghub.elsevier.com/retrieve/pii/S0140673620305663.","References":[]},{"title2":"Opportunistic infections after conversion to belatacept in kidney transplantation","References":[{"title3":"Reduced exposure to calcineurin inhibitors in renal transplantation"},{"title3":"The safety of calcineurin inhibitors for kidney-transplant patients"},{"title3":"The natural history of chronic allograft nephropathy"},{"title3":"Calcineurin Inhibitor Nephrotoxicity through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras"},{"title3":"Costimulation Blockade in Kidney Transplantation: An Update"},{"title3":"Costimulation blockade with belatacept in renal transplantation"},{"title3":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)"},{"title3":"Belatacept and Long-Term Outcomes in Kidney Transplantation"},{"title3":"Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study"},{"title3":"Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension"},{"title3":"New-onset diabetes after kidney transplantation: Risk factors"},{"title3":"Late Conversion from Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters"},{"title3":"De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies"},{"title3":"Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT"},{"title3":"Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: A randomized phase II study"},{"title3":"Opportunistic infections after conversion to belatacept in kidney transplantation"},{"title3":"Glomerular Filtration Rate Measurements in Clinical Trials"},{"title3":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation"},{"title3":"Infection in Organ Transplantation"},{"title3":"Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials"},{"title3":"Subclinical Epstein-Barr virus viremia among adult renal transplant recipients: Incidence and consequences"},{"title3":"BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study"},{"title3":"Risk Stratification for Rejection and Infection after Kidney Transplantation"},{"title3":"Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study"},{"title3":"Risk of posttransplant lymphoproliferative disorder associated with use of belatacept"},{"title3":"Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients"},{"title3":"Infection Rates in Tacrolimus versus Cyclosporine Treated Pediatric Kidney Transplant Recipients on a Rapid Discontinuation of Prednisone Protocol: 1-year Analysis"},{"title3":"Safety and Efficacy Outcomes 3 Years After Switching to Belatacept from a Calcineurin Inhibitor in Kidney Transplant Recipients: Results from a Phase 2 Randomized Trial"},{"title3":"Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity"},{"title3":"Experience with belatacept rescue therapy in kidney transplant recipients"},{"title3":"Epidemiology, Risk Factors, and Outcomes of Opportunistic Infections after Kidney Allograft Transplantation in the Era of Modern Immunosuppression: A Monocentric Cohort Study"},{"title3":"A retrospective study to describe the epidemiology and outcomes of opportunistic infections after abdominal organ transplantation"}]},{"title2":"World Health Organization. Clinical management of severe acute respiratory infection (SARI) when Covid-19 disease is suspected. Interim guidance, 13 March 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed April 20, 2020.","References":[]},{"title2":"Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment","References":[]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: adescriptivestudy"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever"},{"title3":"Coronavirus infections-more than just the common cold"},{"title3":"The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study"},{"title3":"Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill"},{"title3":"Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study"}]}]},{"title1":"Threatening drug?drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID?19)","References":[{"title2":"The first two cases of 2019-nCoV in Italy: where they come from?","References":[{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-the latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"The 2019-new coronavirus epidemic: evidence for virus evolution"},{"title3":"MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization"},{"title3":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT"},{"title3":"jModelTest 2: more models, new heuristics and parallel computing"},{"title3":"Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen)"},{"title3":"Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10"},{"title3":"Accurate model selection of relaxed molecular clocks in bayesian phylogenetics"},{"title3":"Relaxed phylogenetics and dating with confidence"},{"title3":"Posterior summarization in Bayesian phylogenetics using Tracer 1.7"},{"title3":"Emerging understandings of 2019-nCoV"}]},{"title2":"Coronavirus disease 2019: implications of emerging infections for transplantation","References":[{"title3":"Disease outbreak news: Novel Coronavirus - Republic of Korea (ex-China). January 21, 2020. https://www.who.int/csr/don/21-january-2020-novel-coronavirus-republic-of-korea-ex-china/en. Accessed February 8, 2020."},{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Novel coronavirus (2019-nCoV). https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed February 15, 2020."},{"title3":"2019 novel coronavirus (2019-nCoV). https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed February 15, 2020."},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person -to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Severe acute respiratory syndrome (SARS) in the liver transplant recipient and guidelines for donor SARS screening"},{"title3":"MERS CoV infection in two renal transplant recipients: case report"},{"title3":"2019-novel Coronavirus (2019-nCoV): estimated the case fatality rate-a word of caution"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Important information for blood establishments regarding the novel coronavirus outbreak. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-information-blood-establishments-regarding-novel-coronavirus-outbreak. Accessed February 15, 2020."},{"title3":"Red Cross media statement on 2019 novel coronavirus. https://www.redcross.org/about-us/news-and-events/press-release/2020/red-cross-media-statement-on-2019-novel-coronavirus.html. Accessed February 16, 2020."},{"title3":"Cluster of pneumonia cases caused by a novel coronavirus, Wuhan, China 17 January 2020. https://www.ecdc.europa.eu/sites/default/files/documents/Risk%20assessment%20-%20pneumonia%20Wuhan%20China%2017%20Jan%202020.pdf. Accessed February 16, 2020."},{"title3":"Arenaviruses and West Nile virus in solid organ transplant recipients: guidelines from the American Society of transplantation infectious diseases community of practice"},{"title3":"An update and guidance on 2019 novel coronavirus (2019-nCov) pretransplant ID clinicians: Updated 27 January 2020. https://tts.org/23-tid/tid-news/657-tid-update-and-guidance-on-2019-novel-coronavirus-2019-ncov-for-transplant-id. Accessed February 16, 2020."},{"title3":"Information for transplant programs and OPOs regarding 2019 novel Coronavirus. https://optn.transplant.hrsa.gov/news/information-for-transplant-programs-and-opos-regarding-2019-novel-coronavirus/. Accessed February 9, 2020."}]},{"title2":"Severe acute respiratory syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening","References":[{"title3":"World Health Organization. Cumulative Number of Reported Cases of Severe Acute Respiratory Syndrome (SARS). Available at http://www.who.int/csr/sarscountry/2003_04-10/en/"},{"title3":"World Health Organization. Case Definitions for Surveillance of Severe Acute Respiratory Syndrome (SARS). Available at http://www.who.int/csr/sars/casedefinition/en"},{"title3":"Peiris JSM, Lai ST, Poon LLM et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. Available at http://www.thelancet.com/journal/vol361/iss9365/full/llan.361.9365.early_online_publication.25296.1"},{"title3":"Ksiazek TG, Erdman D, Goldsmith C et al. A novel coronaviruses associated with severe acute respiratory syndrome. N Engl J Med. Available at http://content.nejm.org/cgi/content/abstract/NEJMoa030781v1."},{"title3":"Drosten C, Gunther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome N Engl J Med. Available at http://content.nejm.org/cgi/content/abstract/NEJMoa030747v1."},{"title3":"Poutanen SM, Low DE, Henry B et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. Available at http://content.nejm.org/cgi/content/abstract/NEJMoa030634v1."},{"title3":"Amplification of the full-length hepatitis A virus genome by long reverse transcription-PCR and transcription of infectious RNA directly from the amplicon"},{"title3":"World Health Organization. Severe Acute Respiratory Syndrome (SARS). Available at http://www.who.int/csr/sars/en."},{"title3":"Lee N, Hui D, Wu A et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. Available at http://content.nejm.org/cgi/content/abstract/NEJMoa030685v1"}]},{"title2":"MERS CoV infection in two renal transplant recipients: case report","References":[{"title3":"High incidence but low burden of coronaviruses and preferential associations between respiratory viruses"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: A prospective descriptive study"},{"title3":"Middle East Respiratory Syndrome-Coronavirus (MERS-CoV): A case-control study of hospitalized patients"},{"title3":"First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013"},{"title3":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study"},{"title3":"Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction"},{"title3":"World Health Organization (WHO). Revised interim case definition for reporting to WHO - Middle East respiratory syndrome coronavirus (MERS-CoV). Interim case definition as of 3 July 2013. Geneva: WHO, 2013. Available at: http://www.who.int/csr/disease/coronavirus_infections/case_definition/en/index.html. Accessed July 20, 2013."},{"title3":"Centers for Disease Control and Prevention (CDC). Middle East Respiratory Syndrome (MERS). Case Definitions. Available at: http://www.cdc.gov/coronavirus/mers/case-def.html. Accessed June 12, 2013."},{"title3":"In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) coronavirus infection"},{"title3":"Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin"},{"title3":"Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques"},{"title3":"Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: An observational study"},{"title3":"Interferon-beta and mycophenolic acid are potent inhibitors of middle east respiratory syndrome coronavirus in cell-based assays"},{"title3":"Hospital outbreak of Middle East respiratory syndrome coronavirus"}]},{"title2":"Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Transmission of 2019-nCoV infection from an asymptomatic contact in Germany"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"KDIGO clinical practice guideline for the care of kidney transplant recipients"},{"title3":"Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Corticosteroids as adjunctive therapy in the treatment of influenza"},{"title3":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury"}]},{"title2":"Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation?","References":[{"title3":"World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report - 44. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200304-sitrep-44-covid-19.pdf?sfvrsn=783b4c9d_6."},{"title3":"Respiratory disease in the immunosuppressed patient"},{"title3":"Safety of mTOR inhibitors in adult solid organ transplantation"},{"title3":"Ministerio de Sanidad. Gobierno de Espana. Enfermedad por el coronavirus (COVID-19) - Situacion actual. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_37B_COVID-19_18.00. Accessed March 16, 2020."},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Lymphopenia predicts disease severity of COVID- 19: a descriptive and predictive study"},{"title3":"Protecting health-care workers from subclinical coronavirus infection"},{"title3":"Report of the WHO-China Joint Mission on coronavirus Disease 2019 (COVID-19). 2020;2019:16-24."},{"title3":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19) : China, 2020"}]},{"title2":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China."},{"title3":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province."},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings."},{"title3":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds."},{"title3":"Small molecules targeting severe acute respiratory syndrome human coronavirus."},{"title3":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture."},{"title3":"Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset."},{"title3":"Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome."},{"title3":"Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen."},{"title3":"Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity."},{"title3":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus."},{"title3":"Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays."},{"title3":"Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial."},{"title3":"International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) home page ()."},{"title3":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection."},{"title3":"Coronavirus disease (COVID-2019) R&amp;D. Geneva: World Health Organization ()."},{"title3":"National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. London: Royal College of Physicians, 2017 ()."},{"title3":"Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study."},{"title3":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data."},{"title3":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09."},{"title3":"Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes."},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study."},{"title3":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients."},{"title3":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus."}]},{"title2":"COVID-19: consider cytokine storm syndromes and immunosuppression","References":[{"title3":"Coronavirus disease 2019 (COVID-19)situation report - 52"},{"title3":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China"},{"title3":"Adult haemophagocytic syndrome"},{"title3":"Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis"},{"title3":"Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury"},{"title3":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase iii trial"},{"title3":"A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)"},{"title3":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease"},{"title3":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome"}]},{"title2":"Kidney impairment is associated with in-hospital death of COVID-19 patients","References":[]},{"title2":"Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipients","References":[]}]},{"title1":"Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report","References":[{"title2":"Respiratory viral infections in solid organ and hematopoietic stem cell transplantation","References":[{"title3":"The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy"},{"title3":"Viral respiratory infections diagnosed by multiplex PCR after allogeneic hematopoietic stem cell transplantation: long-term incidence and outcome"},{"title3":"Epidemiology and immediate indirect effects of respiratory viruses in lung transplant recipients: a 5-year prospective study"},{"title3":"Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study"},{"title3":"Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients"},{"title3":"Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies"},{"title3":"Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study"},{"title3":"Respiratory viral infections within one year after pediatric lung transplant"},{"title3":"Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience"},{"title3":"Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies"},{"title3":"Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment"},{"title3":"Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients"},{"title3":"Disseminated bocavirus infection after stem cell transplant"},{"title3":"Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center"},{"title3":"Respiratory viruses and chronic rejection in lung transplant recipients"},{"title3":"Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death"},{"title3":"A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients"},{"title3":"Symptomatic respiratory virus infection and chronic lung allograft dysfunction"},{"title3":"Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation"},{"title3":"Infections and neutrophils in the pathogenesis of bronchiolitis obliterans syndrome in children after allogeneic stem cell transplantation"},{"title3":"Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the development of life-threatening acute and chronic alloimmune lung syndromes"},{"title3":"Potential utility of multiplex amplification respiratory viral panel testing in the management of acute respiratory infection in children: a retrospective analysis"},{"title3":"A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients"},{"title3":"Long-term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders"},{"title3":"Comparison of respiratory virus shedding by conventional and molecular testing methods in patients with haematological malignancy"},{"title3":"Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients"},{"title3":"Comparative study of nasopharyngeal aspirate and nasal swab specimens for diagnosis of acute viral respiratory infection"},{"title3":"What is the added benefit of oropharyngeal swabs compared to nasal swabs alone for respiratory virus detection in hospitalized children aged &lt;10 years?"},{"title3":"Identification of respiratory viruses in adults: nasopharyngeal versus oropharyngeal sampling"},{"title3":"Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients"},{"title3":"Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab"},{"title3":"Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee"},{"title3":"Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond"},{"title3":"Successful prevention of respiratory syncytial virus nosocomial transmission following an enhanced seasonal infection control program"},{"title3":"Masks for prevention of respiratory viruses on the BMT unit: results of a quality initiative"},{"title3":"Universal mask usage for reduction of respiratory viral infections after stem cell transplant: a prospective trial"},{"title3":"Community acquired respiratory viral infections after lung transplantation: clinical features and long-term consequences"},{"title3":"A single-season prospective study of respiratory viral infections in lung transplant recipients"},{"title3":"Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review"},{"title3":"Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection"},{"title3":"Respiratory syncytial virus infection following hematopoietic stem cell transplantation"},{"title3":"RSV infection without ribavirin treatment in pediatric hematopoietic stem cell transplantation"},{"title3":"Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes"},{"title3":"Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease"},{"title3":"Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes"},{"title3":"Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections"},{"title3":"Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children"},{"title3":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection"},{"title3":"Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease"},{"title3":"Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers"},{"title3":"Retrospective evaluation of palivizumab efficacy and safety for RSV prophylaxis in pediatric hematopoietic stem cell transplant patients: a single center experience"},{"title3":"Restrictive palivizumab use does not lead to increased morbidity and mortality in pediatric hematopoietic stem cell transplantation patients"},{"title3":"Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation"},{"title3":"Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant"},{"title3":"Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients"},{"title3":"Management of RSV infections in adult recipients of hematopoietic stem cell transplantation"},{"title3":"Ribavirin aerosol approved for severe cases of RSV in infants and young children"},{"title3":"Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative"},{"title3":"Community-acquired respiratory viruses"},{"title3":"Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation"},{"title3":"Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection"},{"title3":"Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efficiency"},{"title3":"Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation"},{"title3":"A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients"},{"title3":"Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology"},{"title3":"BCSH/BSBMT/UK Clinical Virology Network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation"},{"title3":"Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients"},{"title3":"Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients"},{"title3":"Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients"},{"title3":"Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation"},{"title3":"ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients"},{"title3":"Compassionate use experience with high-titer respiratory syncytial virus (RSV) immunoglobulin in RSV-infected immunocompromised persons"},{"title3":"Efficacy, safety, and pharmacokinetics of a new 10 % liquid intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses in subjects with primary immunodeficiency disease"},{"title3":"Challenges and opportunities in developing respiratory syncytial virus therapeutics"},{"title3":"Oral GS-5806 activity in a respiratory syncytial virus challenge study"},{"title3":"RNA respiratory viruses in solid organ transplantation"},{"title3":"Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study"},{"title3":"The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients"},{"title3":"Clinical characteristics and outcomes of influenza A infection in kidney transplant recipients: a single-center experience"},{"title3":"Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients"},{"title3":"Outcomes of influenza infections in hematopoietic cell transplant recipients: application of an immunodeficiency scoring index"},{"title3":"Influenza vaccination in the organ transplant recipient: review and summary recommendations"},{"title3":"Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged &gt;=18 years"},{"title3":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host"},{"title3":"Vaccination in solid organ transplantation"},{"title3":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host"},{"title3":"Influenza vaccine antibody responses in lung transplant recipients"},{"title3":"Effect of annual influenza immunization on antibody response in lung transplant patients"},{"title3":"The humoral immune response to influenza vaccination in lung transplant patients"},{"title3":"Serological response to influenza A H1N1 vaccine (Pandemrix ) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients"},{"title3":"A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings"},{"title3":"Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients"},{"title3":"Response of transplant recipients to influenza vaccination based on type of immunosuppression: a meta-analysis"},{"title3":"Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(R)) in renal transplant recipients"},{"title3":"Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients"},{"title3":"De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients"},{"title3":"Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series"},{"title3":"Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: a self-controlled case-series"},{"title3":"Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis"},{"title3":"Serological response to influenza vaccine after hematopoetic stem cell transplantation"},{"title3":"Randomized, double blind, study of the safety and immunogenicity of standard-dose trivalent inactivated influenza vaccine versus high-dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplant patients"},{"title3":"Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients"},{"title3":"Successful use of oseltamivir prophylaxis in managing a nosocomial outbreak of influenza A in a hematology and allogeneic stem cell transplant unit"},{"title3":"Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies"},{"title3":"The novel 2009 H1N1 influenza virus pandemic: unique considerations for programs in cardiothoracic transplantation"},{"title3":"Pandemic influenza (H1N1): impact on lung transplant recipients and candidates"},{"title3":"Outcome of influenza infection managed with oseltamivir in lung transplant recipients"},{"title3":"Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus"},{"title3":"Clinical experience with intravenous zanamivir under an emergency IND program in the United States (2011-2014)"},{"title3":"Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial"},{"title3":"Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients"},{"title3":"Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial"},{"title3":"Influenza viruses resistant to neuraminidase inhibitors"},{"title3":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015"},{"title3":"Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation"},{"title3":"Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient"},{"title3":"Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein"},{"title3":"Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein"},{"title3":"Adenovirus in solid organ transplant recipients"},{"title3":"Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation"},{"title3":"Adenovirus causing fever, upper respiratory infection, and allograft nephritis complicated by persistent asymptomatic viremia"},{"title3":"Disseminated adenovirus infection in renal transplant recipients: the role of cidofovir and intravenous immunoglobulin"},{"title3":"Acute kidney injury requiring dialysis secondary to adenovirus nephritis in renal transplant recipient"},{"title3":"A case of adenovirus viremia in a pediatric liver transplant recipient with neutropenia and lymphopenia: who and when should we treat?"},{"title3":"Assessment of adenovirus infection in adult lung transplant recipients using molecular surveillance"},{"title3":"Adenovirus infection in pediatric small bowel transplantation recipients"},{"title3":"Clinical characteristics and outcomes of adenovirus infection of the urinary tract after renal transplantation"},{"title3":"Association of viral genome with graft loss in children after cardiac transplantation"},{"title3":"Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients"},{"title3":"Monitoring of adenovirus (ADV)-specific T cells in a boy with ADV pneumonia and disseminated disease after lung transplantation"},{"title3":"Adenovirus infection in the lung results in graft failure after lung transplantation"},{"title3":"Adenovirus pneumonia in lung transplant recipients"},{"title3":"Poor outcome of adenovirus infections in adult hematopoietic stem cell transplant patients with sustained adenovirus viremia"},{"title3":"Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation"},{"title3":"Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome"},{"title3":"Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease"},{"title3":"Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation"},{"title3":"Treatment of adenovirus disease in stem cell transplant recipients with cidofovir"},{"title3":"Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children"},{"title3":"Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial"},{"title3":"Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients"},{"title3":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation"},{"title3":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT"},{"title3":"Cellular immunotherapy for viral infection after HSC transplantation"},{"title3":"Parainfluenza and influenza virus infections in pediatric organ transplant recipients"},{"title3":"Parainfluenza 3 infections early after kidney or simultaneous pancreas-kidney transplantation"},{"title3":"Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome"},{"title3":"Parainfluenza virus respiratory infection after bone marrow transplantation"},{"title3":"Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time"},{"title3":"Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation"},{"title3":"The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation"},{"title3":"Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome"},{"title3":"Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy"},{"title3":"Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment"},{"title3":"Parainfluenza virus 3 pneumonia in a kidney transplant recipient"},{"title3":"DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient"},{"title3":"Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients"},{"title3":"Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation"},{"title3":"DAS181 for treatment of parainfluenza virus infections in hematopoietic stem cell transplant recipients at a single center"},{"title3":"Cholesterol reducing agents inhibit assembly of type I parainfluenza viruses"},{"title3":"Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes"},{"title3":"Human metapneumovirus in lung transplant recipients: characteristics and outcomes"},{"title3":"Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology"},{"title3":"The human metapneumovirus: a case series and review of the literature"},{"title3":"Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review"},{"title3":"Frequency of human metapneumovirus infection in hematopoietic SCT recipients during 3 consecutive years"},{"title3":"Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients"},{"title3":"Human metapneumovirus infections following hematopoietic cell transplantation: factors associated with disease progression"},{"title3":"Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro"},{"title3":"Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections"},{"title3":"Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin"},{"title3":"Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores"},{"title3":"Adoptive T-cell therapy to prevent and treat human metapneumovirus (hMPV) infections post hematopoietic stem cell transplant (HSCT)"},{"title3":"Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model"},{"title3":"Frequent occult infection with cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis"},{"title3":"Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study"},{"title3":"Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis"},{"title3":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation"},{"title3":"Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis"},{"title3":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials"},{"title3":"Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with CMV pneumonia"},{"title3":"Incidence, risk factors and outcomes of delayed-onset cytomegalovirus disease in a large retrospective cohort of lung transplant recipients"},{"title3":"Airway complications after lung transplantation: contemporary survival and outcomes"},{"title3":"Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients"},{"title3":"Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices"},{"title3":"Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients"},{"title3":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis"},{"title3":"Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients"},{"title3":"High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy"},{"title3":"Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis"},{"title3":"Cytomegalovirus immunoglobulin for prophylaxis and treatment of cytomegalovirus infection in the (Val)ganciclovir era: a single-center experience"},{"title3":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review"},{"title3":"Cytomegalovirus in hematopoietic stem cell transplant recipients"},{"title3":"Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial"},{"title3":"Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection"},{"title3":"Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study"},{"title3":"Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation"},{"title3":"Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial"},{"title3":"Recommendations on the use of everolimus in lung transplantation"},{"title3":"Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations"},{"title3":"Cytomegalovirus vaccines under clinical development"},{"title3":"Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial"},{"title3":"Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial"},{"title3":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial"},{"title3":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients"},{"title3":"CMV immunoglobulins for the treatment of CMV infections in thoracic transplant recipients"},{"title3":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation"},{"title3":"Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study"},{"title3":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial"},{"title3":"Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial"},{"title3":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation"},{"title3":"Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy"},{"title3":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT"},{"title3":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation"},{"title3":"Herpes simplex virus infection in heart-lung transplant recipients"},{"title3":"Herpes simplex virus (HSV) pneumonia in a heart transplant: diagnosis and therapy"},{"title3":"Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution"},{"title3":"Herpes simplex virus in solid organ transplantation"},{"title3":"Varicella zoster virus in solid organ transplantation"},{"title3":"Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients"},{"title3":"Pneumonia due to varicella-zoster virus reinfection in a renal transplant recipient"}]},{"title2":"A novel coronavirus from patients with pneumonia in China, 2019","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition"},{"title3":"Importation and human-to-human transmission of a novel coronavirus in Vietnam"},{"title3":"2019 novel coronavirus (2019-nCoV) outbreak: a new challenge"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan"},{"title3":"Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China"},{"title3":"Novel Wuhan (2019-nCoV) coronavirus"},{"title3":"Severe acute respiratory syndrome coronavirus phylogeny: toward consensus"},{"title3":"Diagnosis and treatment of new coronavirus pneumonia (trial version 7) [J / OL]. Tianjin J Tradit Chin Med. 2020;1-5. http://kns.cnki.net/kcms/detail/12.1349.R.20200304.1638.006.html. Accessed 3 June 2020."},{"title3":"Clinical outcome of standardized oxygen therapy nursing strategy in COVID-19"},{"title3":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study"},{"title3":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission"},{"title3":"Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus"},{"title3":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection"},{"title3":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation"},{"title3":"Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways"},{"title3":"Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome"},{"title3":"Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV"},{"title3":"Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients"},{"title3":"Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study"},{"title3":"C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early"},{"title3":"Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study"},{"title3":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China"},{"title3":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Human ipsc-derived cardiomyocytes are susceptible to Sars-Cov-2 infection"},{"title3":"Cardiovascular complications in COVID-19"},{"title3":"COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?"},{"title3":"Endothelial cell infection and endotheliitis in COVID-19"}]},{"title2":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","References":[{"title3":"CHP closely monitors cluster of pneumonia cases on Mainland"},{"title3":"CHP provides further information on cluster of pneumonia cases in Wuhan"},{"title3":"Wuhan wet market closes amid pneumonia outbreak"},{"title3":"Viral load in patients infected with pandemic H1N1 2009 influenza A virus"},{"title3":"Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study"},{"title3":"Evaluation of NxTAG Respiratory pathogen panel and comparison with xTAG respiratory viral panel fast v2 and film array respiratory panel for detecting respiratory pathogens in nasopharyngeal aspirates and swine/avian-origin influenza A subtypes in culture isolates"},{"title3":"Coronavirus as a possible cause of severe acute respiratory syndrome"},{"title3":"Zika virus infection in dexamethasone-immunosuppressed mice demonstrating disseminated infection with multi-organ involvement including orchitis effectively treated by recombinant type I interferons"},{"title3":"High prevalence of four novel astrovirus genotype species identified from rodents in China"},{"title3":"Metagenomic analysis of viromes of dromedary camel fecal samples reveals large number and high diversity of circoviruses and picobirnaviruses"},{"title3":"Identification of a novel bat papillomavirus by metagenomics"},{"title3":"Metagenomic nanopore sequencing of influenza virus direct from clinical respiratory samples"},{"title3":"Severe acute respiratory syndrome (SARS) coronavirus ORF8 protein is acquired from SARS-related coronavirus from greater horseshoe bats through recombination"},{"title3":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study"},{"title3":"Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection"},{"title3":"A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003-2004 community outbreak of SARS in Guangzhou, China"},{"title3":"Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome"},{"title3":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease"},{"title3":"Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus"},{"title3":"Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection"},{"title3":"Viral loads in clinical specimens and SARS manifestations"},{"title3":"Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome"},{"title3":"Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia"},{"title3":"Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus"},{"title3":"Discovery of a novel coronavirus, China Rattus coronavirus HKU24, from Norway rats supports the murine origin of Betacoronavirus 1 and has implications for the ancestor of Betacoronavirus lineage A"},{"title3":"Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats"},{"title3":"Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats"},{"title3":"Bats are natural reservoirs of SARS-like coronaviruses"},{"title3":"Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43"}]},{"title2":"Importation and human-to-human transmission of a novel coronavirus in Vietnam","References":[{"title3":"A novel coronavirus from patients with pneumonia in China, 2019."},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."}]},{"title2":"WHO. Coronavirus disease 2019 (COVID-19) Situation Report -95. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/","References":[]},{"title2":"office Nh. Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 5th Edition). http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.html. 2020.","References":[]},{"title2":"Lopinavir; A potent drug against coronavirus infection: insight from molecular docking study","References":[{"title3":"Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy"},{"title3":"Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal"},{"title3":"The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications"},{"title3":"Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmental"},{"title3":"Role of the endocannabinoid system in diabetes and diabetic complications"},{"title3":"Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men"},{"title3":"Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors"},{"title3":"The anti-obesity effect of rimonabant is associated with an improved serum lipid profile"},{"title3":"Adipocyte-derived hormone levels in HIV lipodystrophy"},{"title3":"Indinavir induces acute and reversible peripheral insulin resistance in rats"},{"title3":"HIV protease inhibitors acutely impair glucose-stimulated insulin release"},{"title3":"Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy"},{"title3":"Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors"},{"title3":"The endocannabinoid system and its therapeutic exploitation"},{"title3":"Dose translation from animal to human studies revisited"},{"title3":"Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats"},{"title3":"Measurement of Glucose Homeostasis In Vivo: Glucose and Insulin Tolerance Tests"},{"title3":"Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review"},{"title3":"Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders"},{"title3":"The Endocannabinoid System: Pivotal Orchestrator of Obesity and Metabolic Disease"},{"title3":"A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity"},{"title3":"Role of cannabinoid receptor type 1 in insulin resistance and its biological implications"},{"title3":"Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer"}]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: adescriptivestudy"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever"},{"title3":"Coronavirus infections-more than just the common cold"},{"title3":"The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study"},{"title3":"Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill"},{"title3":"Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study"}]},{"title2":"Transmission of 2019-nCoV infection from an asymptomatic contact in Germany","References":[{"title3":"A novel coronavirus from patients with pneumonia in China, 2019."},{"title3":"China coronavirus: six questions scientists are asking."}]},{"title2":"Viral infections in solid organ transplant recipients: novel updates and a review of the classics","References":[]},{"title2":"Lopinavir/ritonavir: a review of its use in the management of HIV infection","References":[]},{"title2":"Use of neoral C monitoring: a European consensus","References":[]},{"title2":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","References":[]},{"title2":"Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome","References":[]},{"title2":"Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience","References":[{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome"},{"title3":"Treatment of severe acute respiratory syndrome"},{"title3":"Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China"},{"title3":"Development of a standard treatment protocol for severe acute respiratory syndrome"},{"title3":"High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome"},{"title3":"Use of glucocorticoid in treatment of severe acute respiratory syndrome cases"},{"title3":"Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy"},{"title3":"Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak"},{"title3":"Management and prevention of SARS in China"},{"title3":"Medical treatment of viral pneumonia including SARS in immunocompetent adult"},{"title3":"SARS: pharmacotherapy"},{"title3":"High dose intravenous methylprednisolone in the treatment of severe acute respiratory syndrome"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"The clinical characteristics of secondary infections of lower respiratory tract in severe acute respiratory syndrome"},{"title3":"Nosocomial infections and nosocomial pneumonia"},{"title3":"Chinese Medical Association. Guidelines for management of atypical pneumonia (SARS)"},{"title3":"Comparative study of clinical characteristics and prognosis of clinically diagnosed SARS patients with positive and negative serum SARS coronavirus-specific antibodies test"},{"title3":"A preliminary study of serum antibody level in SARS patients"},{"title3":"Severe acute respiratory syndrome (SARS): a challenge for diagnosis and treatment"},{"title3":"Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003"},{"title3":"Glucocorticoid in the treatment of severe acute respiratory syndrome patients: a preliminary report"},{"title3":"Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients"},{"title3":"Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality"},{"title3":"High dose methylprednisolone in a porcine model of ARDS induced by endotoxemia"},{"title3":"Ineffectiveness of high dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock"},{"title3":"High dose corticosteroids in patients with the adult respiratory distress syndrome"},{"title3":"Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome"},{"title3":"Respiratory and cadiovascular management of septic ALI-ARDS and shock"},{"title3":"Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time"},{"title3":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study"},{"title3":"Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome"},{"title3":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome"},{"title3":"Prolonged disturbances ofin vitrocytokine production in patients with severe acute respiratory syndrome treated with ribavirin and steroids"},{"title3":"Report on the investigation of lower extremity osteonecrosis with magnetic resonance imaging in recovered severe acute respiratory syndrome in Guangzhou"},{"title3":"Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids"},{"title3":"Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence"},{"title3":"Avascular necrosis of bone in severe acute respiratory syndrome"}]},{"title2":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients","References":[{"title3":"Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Geneva: World Health Organization, 2004 ()."},{"title3":"Transmission dynamics and control of severe acute respiratory syndrome."},{"title3":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study."},{"title3":"Influenza A virus shedding and infectivity in households."},{"title3":"Transmission of 2019-nCoV infection from an asymptomatic contact in Germany."}]}]},{"title1":"COVID-19 in a Kidney Transplant Patient","References":[{"title2":"Cyclosporin A inhibits the replication of diverse coronaviruses","References":[]},{"title2":"Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East respiratory syndrome coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model","References":[{"title3":"Update on therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)"},{"title3":"Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study"},{"title3":"Middle East respiratory syndrome"},{"title3":"Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures"},{"title3":"Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study"},{"title3":"Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group"},{"title3":"Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model"},{"title3":"MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment"},{"title3":"Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques"},{"title3":"Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin a and interferon-alpha"},{"title3":"Tropism and innate host responses of influenza A/H5N6 virus: an analysis of ex vivo and in vitro cultures of the human respiratory tract"},{"title3":"Regulation of type I interferon responses"},{"title3":"Role of the Akt pathway in mRNA translation of interferon-stimulated genes"},{"title3":"The same Middle East respiratory syndrome-coronavirus (MERS-CoV) yet different outbreak patterns and public health impacts on the far East expert opinion from the rapid response team of the Republic of Korea"},{"title3":"Growth suppressive cytokines and the AKT/mTOR pathway"},{"title3":"Human coronaviruses: a review of virus-host interactions"},{"title3":"Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes"},{"title3":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study"},{"title3":"Person-to-person spread of the MERS coronavirus--an evolving picture"},{"title3":"Mechanisms of type-I- and type-II-interferon-mediated signalling"},{"title3":"Central role of ULK1 in type I interferon signaling"},{"title3":"Cyclosporin a inhibits rotavirus replication and restores interferon-beta signaling pathway in vitro and in vivo"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"}]}]}]}